精彩内容近日,资阳市中心医院公告称,拟遴选引进47款新药以满足临床用药需求,“中化生”领域均有涉及。其中,独家品种(含独家剂型,下同)占比超五成,不乏重组人血小板生成素注射液、桉柠蒎肠溶胶囊等2024年在中国公立医疗机构终端销售额超10亿元的大品种。此次资阳市中心医院拟引进的新药包含6款医保甲类药、36款医保乙类药和5款非医保药;从剂型上看,注射剂及片剂为主力军,各有15个和13个产品在列;按治疗...
Source Link精彩内容近日,资阳市中心医院公告称,拟遴选引进47款新药以满足临床用药需求,“中化生”领域均有涉及。其中,独家品种(含独家剂型,下同)占比超五成,不乏重组人血小板生成素注射液、桉柠蒎肠溶胶囊等2024年在中国公立医疗机构终端销售额超10亿元的大品种。此次资阳市中心医院拟引进的新药包含6款医保甲类药、36款医保乙类药和5款非医保药;从剂型上看,注射剂及片剂为主力军,各有15个和13个产品在列;按治疗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.